Better Therapeutics (NASDAQ:BTTX – Get Rating) is one of 33 publicly-traded companies in the "Health services" industry, but how does it compare to its rivals? We will compare Better Therapeutics to related businesses based on the strength of its valuation, institutional ownership, profitability, risk, dividends, analyst recommendations and earnings.
Institutional and Insider Ownership
7.5% of Better Therapeutics shares are owned by institutional investors. Comparatively, 48.6% of shares of all "Health services" companies are owned by institutional investors. 59.4% of Better Therapeutics shares are owned by company insiders. Comparatively, 21.6% of shares of all "Health services" companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Get
Better Therapeutics alerts:
Valuation and Earnings
This table compares Better Therapeutics and its rivals top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio |
| Better Therapeutics | $10,000.00 | -$40.33 million | -0.74 |
| Better Therapeutics Competitors | $1.36 billion | -$98.47 million | 36.86 |
Better Therapeutics' rivals have higher revenue, but lower earnings than Better Therapeutics. Better Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Analyst Ratings
This is a summary of recent ratings and target prices for Better Therapeutics and its rivals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
| Better Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
| Better Therapeutics Competitors | 7 | 131 | 277 | 0 | 2.65 |
Better Therapeutics presently has a consensus target price of $14.00, suggesting a potential upside of 839.60%. As a group, "Health services" companies have a potential upside of 89.14%. Given Better Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Better Therapeutics is more favorable than its rivals.
Volatility & Risk
Better Therapeutics has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500. Comparatively, Better Therapeutics' rivals have a beta of 1.19, indicating that their average share price is 19% more volatile than the S&P 500.
Profitability
This table compares Better Therapeutics and its rivals' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
| Better Therapeutics | N/A | -200.73% | -114.68% |
| Better Therapeutics Competitors | -325.87% | -676.77% | -37.31% |
Summary
Better Therapeutics beats its rivals on 8 of the 12 factors compared.
About Better Therapeutics
(Get Rating)
Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. Its clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.
Receive News & Ratings for Better Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Better Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
